Immunotolerx Inc. leverages a well-established natural mechanism of immune tolerance. During normal tissue turnover, apoptotic cells expose phosphatidylserine (PS) on their surface. When recognized and taken up by macrophages and dendritic cells via PS receptors, these cells trigger tolerogenic signals, including the expression of TGFb and IL10, and the induction of regulatory T cells (Tregs). This mechanism maintains immune homeostasis and prevents harmful responses.

At Immunotolerx, we translate this biology into a cutting-edge immunotherapy platform. Our PS-containing nanoparticle-based antigen delivery system is designed to re-educate the immune system in an antigen-specific manner, halting disease progression and reversing or preventing unwanted immune responses to auto-antigens and therapeutic proteins.

By harnessing the body’s own tolerance machinery, we aim to deliver precise, durable immune modulation without broad immunosuppression.